What Biogen Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 2 | 4 |
| Total trades | 4 | 79 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 27 | 104,753 |
| Disposed | 1,194 | 38,828 |
| Net activity | −1,167 | +65,925 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Godbout Sean | Chief Accounting Officer | Oct 02 | Withheld — tax / exercise cost · F | −8 | $219.88 | −$1.76K | 1,459 |
| Godbout Sean | Chief Accounting Officer | Oct 02 | Exercise / conversion · M | +27 | — | — | 1,467 |
| Minor Lloyd | Director | Aug 04 | Open-market sale · S | −593 | $200.96 | −$119K | 2,689 |
| Minor Lloyd | Director | Aug 03 | Open-market sale · S | −593 | $203.34 | −$121K | 3,282 |
| Rowinsky Eric K | Director | Jun 09 | Grant / award · A | +1,505 | — | — | 25,844 |
| Langer Susan | Director | Jun 09 | Grant / award · A | +1,505 | — | — | 6,634 |
| Mantas Jesus B | Director | Jun 09 | Grant / award · A | +1,505 | — | — | 11,263 |
| Sherwin Stephen A | Director | Jun 09 | Grant / award · A | +1,505 | — | — | 15,193 |
| Freire Maria C | Director | Jun 09 | Grant / award · A | +2,005 | — | — | 8,820 |
| Minor Lloyd | Director | Jun 09 | Grant / award · A | +1,505 | — | — | 3,875 |
| Pangalos Menelas N | Director | Jun 09 | Grant / award · A | +1,505 | — | — | 3,875 |
| Pangalos Menelas N | Director | Jun 09 | Exercise / conversion · M | +2,370 | — | — | 2,370 |
| Patolawala Monish D | Director | Jun 09 | Grant / award · A | +1,505 | — | — | 5,215 |
| Hawkins William A | Director | Jun 09 | Grant / award · A | +1,505 | — | — | 10,365 |
| Keeney Adam | Head of Corporate Development | May 01 | Withheld — tax / exercise cost · F | −455 | $187.06 | −$85.1K | 6,365 |
| Keeney Adam | Head of Corporate Development | May 01 | Exercise / conversion · M | +939 | — | — | 6,820 |
| Godbout Sean | Chief Accounting Officer | Apr 01 | Withheld — tax / exercise cost · F | −54 | $183.78 | −$9.92K | 1,342 |
| Godbout Sean | Chief Accounting Officer | Apr 01 | Exercise / conversion · M | +181 | — | — | 1,396 |
| Murphy Nicole | Head of Pharm Ops and Tech | Feb 12 | Open-market buy · P | +3 | $195.04 | +$585 | 19,611 |
| Singhal Priya | Head of Development | Feb 09 | Open-market sale · S | −2,660 | $199.83 | −$532K | 8,043 |
Loading...
